In contrast to his liver metastasis, the in situ carcinoma had a somewhat lower tumor mutational burden, lacked PD-L1/2 amplification, and had a distinct PTCH1 mutation, suggesting that the in situ BCC of his skin and the metastatic BCC of his liver were derived from different clones of cells. Here, PTCH1 is linked to in situ carcinoma.